Enanta's research and development efforts are currently focused on the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), and hepatitis B virus (HBV).
2024/3/18 22:23:53
(ENTA:NASDAQ)
Streetwise Reports Articles